E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
Launched by NYU LANGONE HEALTH · Feb 9, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different ways to help people with Opioid Use Disorder (OUD) who also smoke cigarettes. The study aims to see if using electronic cigarettes (e-cigarettes) can help reduce smoking among these individuals, compared to a program that offers counseling and nicotine replacement therapy (NRT), which includes products like patches or gum. The trial is especially important because people with OUD often struggle with smoking, and finding effective ways to help them quit or reduce smoking can improve their overall health.
To participate in this study, you need to be at least 21 years old, currently smoke at least five cigarettes a day, and be in a treatment program for OUD (like methadone or buprenorphine) for at least 12 weeks. You should also be interested in reducing your cigarette smoking. If you join the trial, you can expect support and resources tailored to your needs, whether you choose the e-cigarette or counseling route. It's a great opportunity to explore new ways to improve your health while managing both opioid use and smoking.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Currently smokes 5 or more CPD
- • 2. Age ≥ 21 years
- • 3. Has a diagnosis of Opioid Use Disorder
- • 4. In OUDTP (buprenorphine or methadone) ≥ 12 weeks via self-report or EHR records
- • 5. Stable methadone or buprenorphine dose for two weeks via self-report or EHR records
- • 6. Interested in reducing combustible cigarette (CC) smoking but not necessarily trying to quit
- • 7. Own a mobile phone or have regular access to a mobile phone.
- • 8. Able to provide an additional contact to improve follow-up rates.
- Exclusion Criteria:
- • 1. Does not speak English or Spanish
- • 2. Are pregnant or breastfeeding
- • 3. Not able to provide consent
- • 4. Used tobacco products other than CC in the past 2 weeks (e.g., EC, cigarillo)
- • 5. Currently engaged in an attempt to quit CC smoking
- • 6. Reports having severe chronic obstructive pulmonary disease or asthma (i.e., with exacerbation requiring hospitalization or intubation in the prior 6 months)
- • 7. Reports current major depressive or manic episode, current psychotic disorder, past-year suicide attempt or psychiatric hospitalization, or current suicidal ideation with plan or intent.
About Nyu Langone Health
NYU Langone Health is a premier academic medical center located in New York City, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, NYU Langone Health integrates cutting-edge scientific inquiry with patient-centered care, striving to develop new therapies and improve health outcomes across a wide range of medical conditions. The institution is dedicated to fostering collaboration among researchers, clinicians, and patients, ensuring rigorous adherence to ethical standards and regulatory guidelines in all clinical research initiatives. By leveraging its extensive resources and expertise, NYU Langone Health aims to contribute significantly to the advancement of medical knowledge and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bronx, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Omar El-Shahawy
Principal Investigator
NYU Langone Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials